NCT00118768已完成2 期
A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of the Combination of Pegylated Interferon Alfa Plus NM283 (Valopicitabine) in Treatment-Naive Patients With Chronic Hepatitis C
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 175
- 试验地点
- 19
研究概览
简要总结
This Phase II study is being conducted in treatment-naive patients (no previous antiviral therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the safety and effectiveness of valopicitabine alone and together with Pegylated Interferon (a drug approved by the Food and Drug Administration for the treatment of Hepatitis C infection).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented clinical history of genotype-1 chronic Hepatitis C and compensated liver disease
- •Treatment Naive (patient has received no previous treatment for chronic hepatitis C infection)
- •Other protocol-defined inclusion criteria may apply.
排除标准
- •Patient is pregnant or breastfeeding
- •Patient is co-infected with HIV or Hepatitis B
- •Other protocol-defined exclusion criteria may apply.
研究者
研究点 (19)
Loading locations...
相似试验
终止
2 期
Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus InfectionRespiratory Syncytial Virus InfectionsNCT03656510Janssen Research & Development, LLC246
终止
2 期
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC GenotypeChronic Hepatitis CNCT01384383Gilead Sciences248
已完成
2 期
Viral Therapy in Treating Patients With Metastatic MelanomaRecurrent MelanomaStage IV MelanomaNCT00651157National Cancer Institute (NCI)23
Unknown
2 期
An Adaptive Clinical Trial of Antivirals for COVID-19 InfectionCOVIDNCT04445467Bayside Health190
终止
2 期
Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital SettingCOVID-19NCT04396106Atea Pharmaceuticals, Inc.83